ADC Therapeutics Stock Quote ADCT - Stock Price, News, Charts, Message Board, Trades

Unlock more advanced trading tools

Join ADVFN today

Current Price

4.56

Bid

Ask

Volume

184,797

4.41 Day's Range 4.65

0.359908 52 Week Range 6.04

Market Cap

374.684M

Previous Close

4.78

Open

4.65

Last Trade

4.56

Last Trade Time

13:04:11

Financial Volume

$ 837,791

VWAP

4.5336

Average Volume (3m)

676,145

Shares Outstanding

82,529,549

Dividend Yield

PE Ratio

-1.60

Earnings Per Share (EPS)

-2.84

Revenue

69.56M

Net Profit

-234.53M

ADC Therapeutics SA is a commercial-stage oncology-focused biotechnology company. It is involved in the development of antibody-drug conjugates for patients suffering from hematological malignancies and solid tumors. The company's product candidate includes ZYNLONTA, camidanlumab tesirine, ADCT-602,... ADC Therapeutics SA is a commercial-stage oncology-focused biotechnology company. It is involved in the development of antibody-drug conjugates for patients suffering from hematological malignancies and solid tumors. The company's product candidate includes ZYNLONTA, camidanlumab tesirine, ADCT-602, ADCT-601, ADCT-901, ADCT-701 and ADCT-212. Show more

Sector

Drugs And Proprietary-whsl

Industry

Drugs And Proprietary-whsl

Website

www.adctherapeutics.com

Headquarters

Lausanne, Che

Founded

1970

ADC Therapeutics SA is listed in the Drugs And Proprietary-whsl sector of the New York Stock Exchange with ticker ADCT. The last closing price for ADC Therapeutics was $4.78. Over the last year, ADC Therapeutics shares have traded in a share price range of $ 0.359908 to $ 6.04.

ADC Therapeutics currently has 82,529,549 shares outstanding. The market capitalization of ADC Therapeutics is $374.68 million. ADC Therapeutics has a price to earnings ratio (PE ratio) of -1.60.

ADC Therapeutics Announces Updates on LOTIS-7 Clinical Trial Evaluating ZYNLONTA® in Combination with Glofitamab or Mosunetuzumab in Patients with Relapsed/Refractory B-cell Non-Hodgkin Lymphoma

Dose escalation in Phase 1b trial completed with no dose-limiting toxicities, no or low-grade cytokine release syndrome and no immune effector cell-associated neurotoxicity syndrome across all...

ADC Therapeutics Announces Abstracts Accepted for Presentation at the American Association for Cancer Research (AACR) Annual Meeting

Preclinical data support future clinical development of ADCs targeting Claudin-6 and NaPi2b Additional presentations include clinical and independent preclinical studies evaluating ADCT-601...

Period	Change	Change %	Open	High	Low	Avg. Daily Vol	VWAP
1	-0.39	-7.87878787879	4.95	5.08	4.41	355280	4.78827075	CS
4	0.2	4.5871559633	4.36	5.38	4.11	514124	4.71990645	CS
12	1.39	43.8485804416	3.17	6.04	2.92	676145	4.48905159	CS
26	3.8666	557.629074127	0.6934	6.04	0.359908	708413	2.92361918	CS
52	2.61	133.846153846	1.95	6.04	0.359908	552565	2.46469254	CS
156	-19.88	-81.3420621931	24.44	32	0.359908	423313	6.62365388	CS
260	-25.44	-84.8	30	56.5899	0.359908	383567	10.89990695	CS

Most Active
% Gainers
% Losers

Symbol	Price	Vol.
SGBXSafe and Green Holdings Corporation	$ 0.235399 (63.36%)	108.05M
ACONAclarion Inc	$ 0.4557 (58.23%)	95.66M
YYGHYY Group Holding Ltd	$ 3.38 (49.56%)	16.67M
BRFHBarfresh Food Group Inc	$ 1.4407 (39.87%)	35.96M
PCSAProcessa Pharmaceuticals Inc	$ 2.25 (38.89%)	54.48M
EJHE Home Household Service Holdings Ltd	$ 0.7389 (-74.61%)	10.04M
CSSEChicken Soup for the Soul Entertainment Inc	$ 0.2758 (-35.15%)	12.17M
ATNIATN International Inc	$ 19.38 (-32.52%)	211.03k
CYCCCyclacel Pharmaceuticals Inc	$ 1.563 (-32.04%)	2.98M
BNAIBrand Engagement Network Inc	$ 2.5759 (-30.94%)	173.99k
SGBXSafe and Green Holdings Corporation	$ 0.235399 (63.36%)	108.05M
ACONAclarion Inc	$ 0.4557 (58.23%)	95.66M
SQQQProShares UltraPro Short QQQ	$ 12.1504 (2.88%)	92.97M
TSLATesla Inc	$ 164.4615 (1.44%)	66.24M
PCSAProcessa Pharmaceuticals Inc	$ 2.25 (38.89%)	54.48M